rapifleX MALDI PharmaPulse - Accelerate uHTS with Mass Spectrometry
The rapifleX MALDI PharmaPulse (MPP) accelerates label-free hit finding in drug discovery: rapifleX MPP combines the unambiguousness of mass spectrometry with the required speed to comb through large compound libraries of millions of substances.
The use of mass spectrometry allows the measurement of unmodified substrates in primary screens to avoid false positives or false negatives, making confirmation screens redundant. The system is designed for fully automatic handling of 1536 sample plates to screen more than a million compounds in a week in support of drug discovery.
New standard for ultra-High-Throughput Screening Label-Free ‘Hit’ Identification
By combining the speed of Bruker’s patented Smartbeam™ 3D laser technology with the direct-detection capability of mass spectrometry, the rapifleX MALDI PharmaPulse (MPP) delivers unprecedented screening capability for High-Throughput Screening biochemical assays. It allows you to screen through large and diverse compound libraries at a pace of over a million compounds a week, epitomizing the perfect balance of automation and miniaturization.
Active Questions & AnswersAsk a Question
There are no current Discussions
Features of rapifleX MALDI PharmaPulse
The MPP system allows for the measurement of unmodified substrates in primary biochemical screens, and offers several advantages:
- It effectively eliminates confirmatory assays typically required of traditional fluorescence-based screening techniques
- Saves costs for developing specific fluorescence probes or antibodies
- Doesn’t require expensive solvents or consumables for continuous operation
- Allow sample volume down to 25nl
There are no General Specifications available.